Nonbiological factors, or factors not related to a disease, were found to independently affect the survival of younger patients with acute myeloid leukemia (AML). Specifically, researchers found that insurance status, marital status, and county-level income affected short- and long-term mortality of these patients, according to a study published in Cancer.
“We believe these three factors indicate lack of material and social support preventing young patients from successfully walking the long and difficult road towards a cure,” said lead author Uma Borate, MD, assistant professor in the division of hematology and oncology at the University of Alabama at Birmingham, in a prepared statement.
Borate and colleagues looked at 5,541 patients age 19 to 64 years diagnosed with AML between 2007 and 2011 taken from the Surveillance, Epidemiology, and End Results (SEER) registry. They examined nonbiological factors including marital status, insurance status, and county-level income and education, as well as biological factors, to assess their effect on survival.
The median overall survival of the cohort was 16 months. When the researchers conducted a multivariate analysis, they found that insurance status, marital status, and county-level median household income were all independently associated with survival.
Patients without health insurance or those with Medicaid had a median survival of 13 months compared with 17 months for patients with private insurance. Single and married patients had a median survival of 16 months compared with 13 months for divorced patients and 10 months for widowed patients. Finally, patients in counties with a median household income in the first, second, or third quintile had a median survival of 14 months compared with 17 and 22 months for the fourth and fifth quintile, respectively.
“An increased risk of death was independently linked to being a Medicaid beneficiary, uninsured, single, or divorced or residing in a county with a median household income in the lower three quintiles,” the researchers wrote. “Education and distance to an HSCT [hematopoietic stem cell transplantation] center did not appear to independently predict survival.”
The study also showed that these three factors affected both early and late mortality, and the researchers confirmed this effect among patients known to have received chemotherapy (88.7% of the cohort).
“Health care professionals and institutions caring for patients with AML should be able to identify socially vulnerable patients who may benefit from additional resources and support during their therapy,” the researchers concluded. “Future research should focus on mechanisms by which nonbiological factors negatively affect the outcomes of younger patients with AML and develop tools to minimize their impact.”
Social Factors Affected Survival of Young Patients With AML
Nonbiological factors such as insurance and marital status and county-level income were found to independently affect the survival of younger patients with AML.
Nonbiological factors, or factors not related to a disease, were found to independently affect the survival of younger patients with acute myeloid leukemia (AML). Specifically, researchers found that insurance status, marital status, and county-level income affected short- and long-term mortality of these patients, according to a study published in Cancer.
“We believe these three factors indicate lack of material and social support preventing young patients from successfully walking the long and difficult road towards a cure,” said lead author Uma Borate, MD, assistant professor in the division of hematology and oncology at the University of Alabama at Birmingham, in a prepared statement.
Borate and colleagues looked at 5,541 patients age 19 to 64 years diagnosed with AML between 2007 and 2011 taken from the Surveillance, Epidemiology, and End Results (SEER) registry. They examined nonbiological factors including marital status, insurance status, and county-level income and education, as well as biological factors, to assess their effect on survival.
The median overall survival of the cohort was 16 months. When the researchers conducted a multivariate analysis, they found that insurance status, marital status, and county-level median household income were all independently associated with survival.
Patients without health insurance or those with Medicaid had a median survival of 13 months compared with 17 months for patients with private insurance. Single and married patients had a median survival of 16 months compared with 13 months for divorced patients and 10 months for widowed patients. Finally, patients in counties with a median household income in the first, second, or third quintile had a median survival of 14 months compared with 17 and 22 months for the fourth and fifth quintile, respectively.
“An increased risk of death was independently linked to being a Medicaid beneficiary, uninsured, single, or divorced or residing in a county with a median household income in the lower three quintiles,” the researchers wrote. “Education and distance to an HSCT [hematopoietic stem cell transplantation] center did not appear to independently predict survival.”
The study also showed that these three factors affected both early and late mortality, and the researchers confirmed this effect among patients known to have received chemotherapy (88.7% of the cohort).
“Health care professionals and institutions caring for patients with AML should be able to identify socially vulnerable patients who may benefit from additional resources and support during their therapy,” the researchers concluded. “Future research should focus on mechanisms by which nonbiological factors negatively affect the outcomes of younger patients with AML and develop tools to minimize their impact.”
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease
Administering precision-selected donor regulatory T-cell therapy significantly improves GVHD-free, relapse-free survival in patients undergoing allogeneic HCT.
CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025
An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML
The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.
Highlighting Advancements in Personalized T-Cell Lymphoma Treatment
Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.
BGB-16673 Shows Tolerability, Activity in Waldenström Macroglobulinemia
BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those with disease refractory to prior cBTK and ncBTK inhibition.
EHA 2025: Top 5 Takeaways for Hematologic Malignancy Management
Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.
Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease
Administering precision-selected donor regulatory T-cell therapy significantly improves GVHD-free, relapse-free survival in patients undergoing allogeneic HCT.
CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025
An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML
The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.
Highlighting Advancements in Personalized T-Cell Lymphoma Treatment
Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.
BGB-16673 Shows Tolerability, Activity in Waldenström Macroglobulinemia
BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those with disease refractory to prior cBTK and ncBTK inhibition.
EHA 2025: Top 5 Takeaways for Hematologic Malignancy Management
Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.